

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rogers et al.

Application No. 10/533,414

Filed: April 29, 2005

Confirmation No. 4172

For: N-ACETYL-D-GLUCOSAMINE (NAG)
SUPPLEMENTED FOOD PRODUCTS
AND BEVERAGES

FILED VIA EFS ON JUNE 14, 2007

Examiner: Michael C. Henry

Art Unit: 1623

Attorney Reference No. 6682-66957-02

SUBMITTED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT PURSUANT TO
37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 are several English-language documents. Enclosed is one English-language document. Applicants respectfully request the documents listed on the accompanying form PTO-1449 be listed as references cited on the issued patent. This Information Disclosure Statement (“IDS”) is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Submitted herewith is the fee of \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By


Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6682-66957-02
Application Number	10/533,414
Filing Date	April 29, 2005
First Named Inventor	Rogers
Art Unit	1623
Examiner Name	Michael C. Henry

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		2002/0115639 A2	08/22/2002	Fan et al.
		5,141,964	08/25/1992	Noel

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 01/01992 A1	01/11/2001	SCA LOHNHERSTELLUNGS AG and PHARMA BASE S.A.

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.